Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Address
UGLAND HOUSE, SOUTH CHURCH STREET
GEORGE TOWN, GRAND CAYMAN, E9 KY1-1104
Founded
2013
Number of Employees
99
Website
http://www.theravance.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | - | - | - | $141,454 | $444 | $70,949 |
| Average Price | - | - | - | - | - | - | - | - | - | $10.50 | $11.55 | $10.50 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | 13,476,518 | 38,462 | 6,757,490 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | -23.8% | -30.7% | -23.8% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | 31.3% | 7.4% | 19.4% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | -55.1% | -38.1% | -43.2% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | 16% | 8% | 26% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at TBPH make a trade.
Creating a free account takes less than one minute